Literature DB >> 22579129

Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios.

Odysseas Gregoriou1, Panagiotis Bakas, Charalampos Grigoriadis, Maria Creatsa, Dimitrios Hassiakos, Georgios Creatsas.   

Abstract

OBJECTIVE: To compare the effects of 2.5 mg letrozole with those of 1 mg anastrazole daily on the hormonal and semen profiles of a subset of infertile men with low T/E(2) ratios.
DESIGN: Prospective, nonrandomized study.
SETTING: Reproductive medicine clinic. PATIENT(S): The study group consisted of 29 infertile men with a low serum T/E(2) ratio (<10). INTERVENTION(S): Patients were divided into two groups. Group A included 15 patients treated with 2.5 mg letrozole orally once daily for 6 months, and Group B consisted of 14 patients treated with 1 mg anastrazole orally every day for 6 months. MAIN OUTCOME MEASURE(S): Hormonal evaluation included measurement of serum FSH, LH, PRL, T, and E(2). In all sperm analyses pretreatment and posttreatment total motile sperm counts (ejaculate volume × concentration × motile fraction) were evaluated. RESULT(S): The use of aromatase inhibitors (either letrozole or anastrazole) in cases of infertile men with low T/E(2) ratios improved both hormonal and semen parameters. CONCLUSION(S): This study suggests that some men with severe oligospermia, low T levels, and normal gonadotropin concentration may have a treatable endocrinopathy.
Copyright © 2012 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22579129     DOI: 10.1016/j.fertnstert.2012.04.005

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  16 in total

Review 1.  Novel Therapy for Male Hypogonadism.

Authors:  Robert Carrasquillo; Kevin Chu; Ranjith Ramasamy
Journal:  Curr Urol Rep       Date:  2018-06-09       Impact factor: 3.092

2.  Multivariate analysis to predict letrozole efficacy in improving sperm count of non-obstructive azoospermic and cryptozoospermic patients: a pilot study.

Authors:  Giorgio Cavallini; Giulio Biagiotti; Elisa Bolzon
Journal:  Asian J Androl       Date:  2013-10-14       Impact factor: 3.285

Review 3.  Diagnosis and treatment of infertility-related male hormonal dysfunction.

Authors:  Martin Kathrins; Craig Niederberger
Journal:  Nat Rev Urol       Date:  2016-04-19       Impact factor: 14.432

Review 4.  Hormone-Based Treatments in Subfertile Males.

Authors:  Darshan P Patel; Jason C Chandrapal; James M Hotaling
Journal:  Curr Urol Rep       Date:  2016-08       Impact factor: 3.092

5.  The Role of Estrogen Modulators in Male Hypogonadism and Infertility.

Authors:  Amarnath Rambhatla; Jesse N Mills; Jacob Rajfer
Journal:  Rev Urol       Date:  2016

6.  Effect of Letrozole Administration as a Selective Aromatase Inhibitor on Male Rat's Reproductive Performance.

Authors:  A Hmood Jassim; A S Abed; A Kareem Thamer; H K Judi; A H Enad
Journal:  Arch Razi Inst       Date:  2022-02-28

7.  Comparison of the effect of combined therapy of HCG ampule and letrozole tablet with each method separately on the spermogram parameters in the obese men with idiopathic infertility: a clinical trial.

Authors:  Yadollah Ahmadi-Asrbadr; Mahdi Hemmati-Ghavshough; Navid Khanzadeh; Fereshteh Ansari; Mohsen Mohammad-Rahimi
Journal:  Am J Clin Exp Urol       Date:  2022-08-15

8.  Hyperestrogenism and low serum testosterone-17β-estradiol ratio are associated with non-bacterial male accessory gland inflammation.

Authors:  Rosita A Condorelli; Aldo E Calogero; Sandro La Vignera
Journal:  Int J Immunopathol Pharmacol       Date:  2016-04-18       Impact factor: 3.219

9.  Aromatase inhibitors in male sex.

Authors:  Santosh Kumar Singh
Journal:  Indian J Endocrinol Metab       Date:  2013-10

Review 10.  Current medical management of endocrine-related male infertility.

Authors:  Joshua D Ring; Aye A Lwin; Tobias S Köhler
Journal:  Asian J Androl       Date:  2016 May-Jun       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.